TY  - GEN
AU  - Holkova,Beata
AU  - Zingone,Adriana
AU  - Kmieciak,Maciej
AU  - Bose,Prithviraj
AU  - Badros,Ashraf Z
AU  - Voorhees,Peter M
AU  - Baz,Rachid
AU  - Korde,Neha
AU  - Lin,Hui-Yi
AU  - Chen,Jin-Qiu
AU  - Herrmann,Michelle
AU  - Xi,Liqiang
AU  - Raffeld,Mark
AU  - Zhao,Xiuhua
AU  - Wan,Wen
AU  - Tombes,Mary Beth
AU  - Shrader,Ellen
AU  - Weir-Wiggins,Caryn
AU  - Sankala,Heidi
AU  - Hogan,Kevin T
AU  - Doyle,Austin
AU  - Annunziata,Christina M
AU  - Wellons,Martha
AU  - Roberts,John D
AU  - Sullivan,Daniel
AU  - Landgren,Ola
AU  - Grant,Steven
TI  - A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
SN  - 1557-3265
PY  - 2016///1213
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Benzimidazoles
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - MAP Kinase Kinase Kinases
KW  - antagonists & inhibitors
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Recurrence, Local
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-15-1076
ER  -